<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02763033</url>
  </required_header>
  <id_info>
    <org_study_id>UMCC 2016.029</org_study_id>
    <secondary_id>HUM00112318</secondary_id>
    <nct_id>NCT02763033</nct_id>
  </id_info>
  <brief_title>Dietary Manipulation of the Microbiome-metabolomic Axis for Mitigating GVHD in Allo HCT Patients</brief_title>
  <official_title>Dietary Manipulation of the Microbiome-metabolomic Axis for Mitigating GVHD in Allo HCT Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Michigan Rogel Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Michigan Rogel Cancer Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Investigators are evaluating the feasibility, safety and early efficacy of administering a&#xD;
      commercially available dietary supplement containing potato-based resistant starch to&#xD;
      subjects undergoing allogeneic SCT (stem cell transplant). The intervention will begin&#xD;
      immediately prior to the conditioning phase and continue through day 100. Investigators&#xD;
      hypothesize that short term administration of a resistant starch is capable of increasing&#xD;
      levels of butyrate within the intestine that will reduce rates of acute GVHD&#xD;
      (Graft-Versus-Host Disease).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 26, 2017</start_date>
  <completion_date type="Anticipated">April 2024</completion_date>
  <primary_completion_date type="Anticipated">April 2024</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of grade II-IV GVHD</measure>
    <time_frame>Day 100</time_frame>
    <description>The incidence of grade II, III and IV GVHD (Graft Versus Host Disease) as documented on day 100&#xD;
Grade II: Rash 25-50% of Body Surface Area (BSA), Bilirubin 3.1-6mg/dL, adult stool output 1000-1500mL/day or child 20-30mL/kg/day.&#xD;
Grade III: Rash greater than 50% BSA, bilirubin 6.1-15mg/dL, adult stool output greater than 1500mL/day or child stool output greater than 30mL/kg/day&#xD;
Grade IV: generalized erythroderma plus bullous formation and desquamation greater than 5% BSA, bilirubin greater than 15mg/dL, severe abdominal pain with or without ileus, or grossly bloody stool.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">70</enrollment>
  <condition>Hematopoietic Stem Cell Transplantation</condition>
  <arm_group>
    <arm_group_label>Bob's Red Mill®</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will follow the standard BMT (bone marrow transplant) diet and add potato-starch produced by Bob's Red Mill® beginning on day -7 and continuing through day +100.Patients will consume 20 g of Bob's Red Mill®, Potato-based dietary starch, orally twice daily.&#xD;
Initially, subjects will take 20g daily for first three days prior to increasing dose to 20 g BID.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Starch Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Patients will receive an iso-caloric, non-resistant starch placebo.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bob's Red Mill®</intervention_name>
    <description>Standard bone marrow transplant (BMT) diet + potato-based starch</description>
    <arm_group_label>Bob's Red Mill®</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Starch Placebo</intervention_name>
    <description>Standard bone marrow transplant (BMT) diet + corn-based starch</description>
    <arm_group_label>Bob's Red Mill®</arm_group_label>
    <arm_group_label>Starch Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Subjects undergoing matched related full intensity allogeneic HSCT (hematopoietic stem&#xD;
             cell transplantation)&#xD;
&#xD;
          -  Age ≥ 18 years for the feasibility phase. Age ≥10 years old AND ≥50 kg for the phase&#xD;
             II portion.&#xD;
&#xD;
          -  Karnofsky &gt;70%, (Karnofsky Performance Status: an attempt to quantify cancer patients'&#xD;
             general well-being and activities of daily life. The score ranges from 0 to 100 where&#xD;
             100 is &quot;perfect&quot; health and 0 is death.)&#xD;
&#xD;
          -  Subjects must be able to swallow capsules/tablets&#xD;
&#xD;
          -  Ability to understand and the willingness to sign a written informed consent&#xD;
&#xD;
          -  Willingness to consent / co-enroll on BMT long term follow up study or HUM00043287&#xD;
             (UMCC2001-0234)&#xD;
&#xD;
          -  Availability of an HLA (human leukocyte antigen) matched related donor.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with inflammatory bowel disease.&#xD;
&#xD;
          -  Patients with a history of gastric bypass surgery.&#xD;
&#xD;
          -  Patients with active Clostridium difficile infection at the time of study enrollment.&#xD;
             Active infection is defined as a stool sample positive for Clostridium difficile toxin&#xD;
             via EIA (enzyme immunoassay) and either symptoms (frequent loose stools) OR imaging&#xD;
             findings consistent with toxic megacolon.&#xD;
&#xD;
          -  Patients actively enrolled on any other GVHD prevention trial.&#xD;
&#xD;
          -  Any physical or psychological condition that, in the opinion of the investigator,&#xD;
             would post unacceptable risk to the patient or raise concern that the patient would&#xD;
             not comply with protocol procedures.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>10 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pavan Reddy, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Michigan Rogel Cancer Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Pavan Reddy, M.D.</last_name>
    <phone>734-936-8785</phone>
    <email>reddypr@umich.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Michigan Cancer Center</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pavan Reddy, MD</last_name>
      <phone>734-936-8785</phone>
      <email>reddypr@umich.edu</email>
    </contact>
    <investigator>
      <last_name>Pavan Reddy, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>May 3, 2016</study_first_submitted>
  <study_first_submitted_qc>May 3, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 5, 2016</study_first_posted>
  <last_update_submitted>December 2, 2020</last_update_submitted>
  <last_update_submitted_qc>December 2, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 4, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

